Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma

Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA
Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma ( Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA )
18 Dec 2025

Rusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia vera

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA
Rusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia vera ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )
18 Dec 2025

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany
Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )
17 Dec 2025

COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and a prothrombotic state

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA
COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and a prothrombotic state ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )
17 Dec 2025

MRD validated as a surrogate endpoint for survival in AML

Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA
MRD validated as a surrogate endpoint for survival in AML ( Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA )
17 Dec 2025

Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA
Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )
17 Dec 2025

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA
IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )
17 Dec 2025

Exploring genomic insights in acute lymphoblastic leukaemia treatment

Prof Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA
Exploring genomic insights in acute lymphoblastic leukaemia treatment ( Prof Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA )
17 Dec 2025

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia
AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer ( Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia )
16 Dec 2025

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab ( Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia )
16 Dec 2025

Essential breast cancer medicines

Dr Didier Verhoeven, Prof Helena Earl, Prof Ahmed Magdy and Prof Luiz Gebrim
Essential breast cancer medicines ( Dr Didier Verhoeven, Prof Helena Earl, Prof Ahmed Magdy and Prof Luiz Gebrim )
12 Dec 2025

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types

Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA
New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types ( Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA )
10 Dec 2025